Presented by Dr Manon Mossakowski (CHU UCL Namur, Belgium)
In this video, Dr Manon Mossakowski, medical oncologist at CHU UCL Namur, discusses four abstracts presented during the clinical science symposium on novel therapeutics in salivary gland cancer at ASCO 2026. Salivary gland tumours are a rare and heterogeneous group of head and neck cancers.
The first two studies addressed adenoid cystic carcinoma, a disease with no established standard of care and historically low response rates to chemotherapy, immunotherapy and VEGF-directed therapy. The phase I/II ARIA study evaluated REM-422, an oral MYB mRNA degrader, in recurrent or metastatic adenoid cystic carcinoma.1 MYB dysregulation is a key oncogenic driver in this disease, and REM-422 acts through inclusion of a “poison exon” leading to MYB mRNA degradation. In biomarker-positive patients treated at the recommended phase II dose, the objective response rate (ORR) was 43% and disease control (DCR) reached 100%. Responses were durable and observed across adenoid cystic carcinoma subtypes. The safety profile was favourable at the selected dose, supporting the ongoing phase II ARIA study in biomarker-selected patients.
A second phase I study evaluated emiltatug ledadotin, or Emi-Le, a B7-H4-directed antibody-drug conjugate with a microtubule inhibitor payload, in patients with aggressive adenoid cystic carcinoma.2 B7-H4 is highly expressed in adenoid cystic carcinoma and is associated with poorer outcomes, although expression level itself did not appear to clearly predict response. In the post hoc aggressive ACC population, defined by clinicopathologic features, Emi-Le showed an ORR of 46.9%, including one complete response, with a DCR of 81.3% and median PFS of 7.8 months. Toxicity was considered manageable, mainly consisting of transient and/or low-grade laboratory abnormalities. The most common all grade and grade 3 treatment-related adverse events (TRAEs) included transient AST elevation, asymptomatic and reversible proteinuria, and predominantly low-grade fatigue and nausea. No grade 4 or 5 TRAEs and no alopecia or pneumonitis were observed. These early data support further evaluation in an ongoing phase II study (NCT05377996).
The last two studies addressed salivary gland carcinoma. The phase II MYTHOS trial investigated trastuzumab deruxtecan in HER2-low recurrent or metastatic salivary gland carcinoma (cohort 2).3 Although the prespecified Simon two-stage efficacy threshold was not met, the descriptive full analysis set showed clinically meaningful activity, with an ORR of 38.9% and a DCR of 94.4%. Responses were observed in salivary duct carcinoma, but not in the small non-salivary duct carcinoma subgroup. Median PFS was 8.7 months and median OS was 24.8 months.
Finally, a phase II study evaluated darolutamide plus androgen deprivation therapy in hormone-therapy-naïve recurrent or metastatic androgen receptor-positive salivary gland cancers.4 Androgen receptor expression is most frequently seen in salivary duct carcinoma, which was the predominant histology in this trial (14/20 patients, 70%). The primary endpoint, confirmed best ORR, was 40%. The clinical benefit rate was 90%. Responses were rapid and durable in several patients, and treatment was well tolerated, with no new safety signals and no darolutamide dose reductions or holds due to adverse events. Exploratory analyses suggested that HER2 status and biological sex may influence benefit, but these observations remain hypothesis-generating. Together, the data support androgen receptor blockade as a relevant strategy in selected patients with androgen receptor-positive salivary gland cancer.
Reference:
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in